Alder BioPharma (ALDR) Announces Presentation of Positive ALD403 Phase 2b Data in Migraine Prevention
Tweet Send to a Friend
Alder BioPharmaceuticals, Inc. (Nasdaq: ALDR) announced the presentation of data from Phase 2b and Phase 1 clinical trials of ALD403 ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
